International: +1-347-960-6455
Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Advanced Regulatory Approaches by the Drug Developers

According to a new research report Progressive Supranuclear Palsy (PSP) Therapeutics – Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, PSP therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

PSP Therapeutics Pipeline Insights

PSP is identified as a rare brain disorder, which affects the control of eye movement and walking. Individuals with PSP also face difficulty in swallowing, speaking, and controlling other voluntary movements. This disease slowly progresses and damages nuclei of neurons in brain. Neuropsychological testing, magnetic resonance imaging (MRI), and eye movement physical examinations are used to diagnose PSP.

As per the current scenario, there is no marketed products available for primary treatment of PSP. Some symptomatic treatments available for PSP include physiotherapy, change in diet plan, speech and language therapy, occupational therapy, and intake of anti-depressants.

Insights into Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage of this is that the entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for PSP through intravenous route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive PSP Therapeutics Pipeline

Companies that are involved in developing therapeutics for PSP have shown positive clinical results in various phases of drug development. For instance, in October 2018, Biogen Inc. announced positive results of phase II trial of its drug candidate “BIIB092” for the treatment of PSP. The results of the study concluded that BIIB092 was generally well-tolerated among patients.

Browse Detailed Report at:

Designation Grants by Regulatory Bodies to Accelerate the Development Process of PSP Therapeutics

Since there is no marketed products for PSP, companies are actively seeking designation grants to accelerate the process of development. For instance, in July 2018, Asceneuron SA received Orphan Drug Designation by the United States Food and Drug Administration (USFDA) for its potential therapeutic candidate, ASN120290, for the treatment of PSP.

AbbVie Inc., Déclion Inc., Alectos Therapeutics Inc., Prothena Corporation plc, Asceneuron SA, Prana Biotechnology Limited, Biogen Inc., and AlzProtect S.A.S. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of PSP.

PSP Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PSP. Comprehensive insights of the pipeline phase products have been provided with special focus on strategic development activities, inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PSP therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to PSP.